Actinium Pharmaceuticals Under Fire: Class Action Lawsuit Notification
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) finds itself in hot water as investors are being informed of a class action lawsuit led by the law firm Levi & Korsinsky, LLP. This action comes as a result of alleged securities fraud that impacted shareholders during the period from October 31, 2022, to August 2, 2024.
Understanding the Case
The lawsuit claims that officials at Actinium made misleading statements about the potential approval of their targeted radiotherapy, Iomab-B BLA. Specifically, the complaint highlights four key allegations:
1.
Pivotal Trial Data Misrepresentation: The lawsuit asserts that the data from the Phase 3 Sierra trial did not meet the FDA's approval criteria for the product.
2.
Ineffectiveness of Additional Analyses: It alleges that the further analyses provided to the FDA, which were intended to demonstrate an improvement in overall survival rates, were not enough to convince the agency of the product's efficacy.
3.
FDA Review Likelihood: The complaint indicates that the FDA was unlikely to either review or approve the application in its current form.
4.
Misleading Statements on Business Viability: The defendants are accused of making positive claims regarding the business’s prospects that were ultimately found to be unfounded.
Importance of Timing
Affected investors have until May 27, 2025, to act. Individuals who experienced financial losses due to the alleged misconduct are being encouraged to step forward and request the court to appoint them as lead plaintiff. Even those who do not serve in this role can still benefit from any potential financial recovery resulting from the lawsuit.
No Costs to Participants
For those who qualify, participation in this class action lawsuit comes at no upfront cost. Class members may obtain compensation without incurring personal expenses or fees, making this an accessible avenue for justice and recovery.
Why Choose Levi & Korsinsky?
Levi & Korsinsky boasts an extensive history of advocating for shareholders' rights. Over the past two decades, the firm has accumulated an impressive track record that includes securing hundreds of millions of dollars for clients harmed by securities fraud. With a dedicated team of over 70 professionals, they stand ready to handle complex securities litigation, having been recognized consistently as one of the top law firms in this field.
Contact Information
Investors wishing to learn more or join the class action can contact Levi & Korsinsky directly:
- - Email: Joseph E. Levi, Esq.
- - Phone: (212) 363-7500
- - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
This lawsuit highlights the importance of transparency and accountability in the pharmaceutical sector. For investors in Actinium Pharmaceuticals, staying informed and proactive is crucial as this case unfolds.